OX2 Therapeutics is a biotechnology company based in Fremont, CA that has received FDA approval for its novel peptide ligand checkpoint inhibitor, CD200AR-L, for the treatment of central nervous system tumors, specifically high-grade glioblastoma. This first-of-its-kind peptide is designed to target CD200 activation receptors and modulate the immune system, overcoming immunosuppressive barriers in the tumor microenvironment. OX2 Therapeutics aims to develop CD200AR-L as a platform for the potential treatment of other solid tumors.
With promising results from survival studies conducted on mice and dogs, OX2 Therapeutics' CD200AR-L has shown an increased anti-tumor response and a two-year progression-free survival rate of 20% in canine glioma cases. The peptide has demonstrated no systemic toxicity or adverse effects, making it a potential breakthrough in cancer therapy. OX2 Therapeutics is dedicated to advancing the clinical development of CD200AR-L and harnessing the power of immunotherapy to revolutionize cancer treatment.
Generated from the website